Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis

Abstract The aim of this study was to assess the prevalence of cardiovascular risk factors in TAK, to describe the use of aspirin and statins and the risk factors associated with vascular ischemic complications and relapses. We conducted a retrospective study on TAK patients diagnosed between 2010 a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Charlotte Laurent, Sergio Prieto-González, Pierre Belnou, Fabrice Carrat, Olivier Fain, Azeddine Dellal, Maria C. Cid, José Hernández-Rodríguez, Arsène Mekinian
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/c38fe663bfbe493b8453eccfb5a6f005
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c38fe663bfbe493b8453eccfb5a6f005
record_format	dspace
spelling	oai:doaj.org-article:c38fe663bfbe493b8453eccfb5a6f0052021-12-02T15:33:01ZPrevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis10.1038/s41598-021-93416-02045-2322https://doaj.org/article/c38fe663bfbe493b8453eccfb5a6f0052021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-93416-0https://doaj.org/toc/2045-2322Abstract The aim of this study was to assess the prevalence of cardiovascular risk factors in TAK, to describe the use of aspirin and statins and the risk factors associated with vascular ischemic complications and relapses. We conducted a retrospective study on TAK patients diagnosed between 2010 and 2018. Demographic, clinical, laboratory data and treatments were evaluated at diagnosis and during the follow-up. We included fifty-two TAK patients with median age 37.5 years [range 16–53] and 43 (83%) women. At diagnosis, cardiovascular risk factors were present in 32 (62%) patients: hypertension (n = 20, 38%), hyperlipidemia (n = 8, 15%), tobacco use (n = 16, 31%). During the median 4-year follow-up [range 0.1–17 years], 17 (33%) patients had at least one ischemic event and 15 (29%) patients needed endovascular procedure. Whereas TAK patients with cardiovascular risk factors were more frequently on statins and anti-hypertensive drugs, they have higher rates of cumulative ischemic complications (5 (24%) versus 21 (67%); p = 0.004), but similar rates of aspirin-treated patients. Patients who have developed vascular ischemic events were more frequently smokers (53% versus 20%; p = 0.03). The vascular complication-free survival was not significantly different in TAK patients with or without statins or aspirin at diagnosis. During the follow-up, 27 (52%) patients had at least one relapse, and the relapse-free survival was not significantly different in patients treated with statins or aspirin. Cardiovascular risk factors in TAK have to be strictly controlled since these risk factors could be associated with increased risk of ischemic complications.Charlotte LaurentSergio Prieto-GonzálezPierre BelnouFabrice CarratOlivier FainAzeddine DellalMaria C. CidJosé Hernández-RodríguezArsène MekinianNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-6 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Charlotte Laurent Sergio Prieto-González Pierre Belnou Fabrice Carrat Olivier Fain Azeddine Dellal Maria C. Cid José Hernández-Rodríguez Arsène Mekinian Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis
description	Abstract The aim of this study was to assess the prevalence of cardiovascular risk factors in TAK, to describe the use of aspirin and statins and the risk factors associated with vascular ischemic complications and relapses. We conducted a retrospective study on TAK patients diagnosed between 2010 and 2018. Demographic, clinical, laboratory data and treatments were evaluated at diagnosis and during the follow-up. We included fifty-two TAK patients with median age 37.5 years [range 16–53] and 43 (83%) women. At diagnosis, cardiovascular risk factors were present in 32 (62%) patients: hypertension (n = 20, 38%), hyperlipidemia (n = 8, 15%), tobacco use (n = 16, 31%). During the median 4-year follow-up [range 0.1–17 years], 17 (33%) patients had at least one ischemic event and 15 (29%) patients needed endovascular procedure. Whereas TAK patients with cardiovascular risk factors were more frequently on statins and anti-hypertensive drugs, they have higher rates of cumulative ischemic complications (5 (24%) versus 21 (67%); p = 0.004), but similar rates of aspirin-treated patients. Patients who have developed vascular ischemic events were more frequently smokers (53% versus 20%; p = 0.03). The vascular complication-free survival was not significantly different in TAK patients with or without statins or aspirin at diagnosis. During the follow-up, 27 (52%) patients had at least one relapse, and the relapse-free survival was not significantly different in patients treated with statins or aspirin. Cardiovascular risk factors in TAK have to be strictly controlled since these risk factors could be associated with increased risk of ischemic complications.
format	article
author	Charlotte Laurent Sergio Prieto-González Pierre Belnou Fabrice Carrat Olivier Fain Azeddine Dellal Maria C. Cid José Hernández-Rodríguez Arsène Mekinian
author_facet	Charlotte Laurent Sergio Prieto-González Pierre Belnou Fabrice Carrat Olivier Fain Azeddine Dellal Maria C. Cid José Hernández-Rodríguez Arsène Mekinian
author_sort	Charlotte Laurent
title	Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis
title_short	Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis
title_full	Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis
title_fullStr	Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis
title_full_unstemmed	Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis
title_sort	prevalence of cardiovascular risk factors, the use of statins and of aspirin in takayasu arteritis
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/c38fe663bfbe493b8453eccfb5a6f005
work_keys_str_mv	AT charlottelaurent prevalenceofcardiovascularriskfactorstheuseofstatinsandofaspirinintakayasuarteritis AT sergioprietogonzalez prevalenceofcardiovascularriskfactorstheuseofstatinsandofaspirinintakayasuarteritis AT pierrebelnou prevalenceofcardiovascularriskfactorstheuseofstatinsandofaspirinintakayasuarteritis AT fabricecarrat prevalenceofcardiovascularriskfactorstheuseofstatinsandofaspirinintakayasuarteritis AT olivierfain prevalenceofcardiovascularriskfactorstheuseofstatinsandofaspirinintakayasuarteritis AT azeddinedellal prevalenceofcardiovascularriskfactorstheuseofstatinsandofaspirinintakayasuarteritis AT mariaccid prevalenceofcardiovascularriskfactorstheuseofstatinsandofaspirinintakayasuarteritis AT josehernandezrodriguez prevalenceofcardiovascularriskfactorstheuseofstatinsandofaspirinintakayasuarteritis AT arsenemekinian prevalenceofcardiovascularriskfactorstheuseofstatinsandofaspirinintakayasuarteritis
_version_	1718387167334498304

Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis

Ejemplares similares